Stockscreener 앱 받기
3.59
6.02%
-0.23
시장 영업 전:
3.55
-0.04
-1.11%
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com
Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex
Larimar Therapeutics Inc (LRMR)’s stock chart: A technical perspective - US Post News
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $20.13 Average Price Target from Brokerages - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Truist Financial - MarketBeat
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Bought by JPMorgan Chase & Co. - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Buy” from Analysts - Defense World
Truist Financial Initiates Coverage on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar started at buy by Truist on Friedreich's ataxia drug - MSN
Truist Initiates Larimar Therapeutics at Buy With $18 Price Target -January 29, 2025 at 06:37 am EST - Marketscreener.com
Larimar Therapeutics Aligns Executive Incentives with Milestones - MSN
Larimar Therapeutics awards key executives performance-based stock By Investing.com - Investing.com Australia
Larimar Therapeutics awards key executives performance-based stock - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment - MSN
JMP Securities maintains $21 target on Larimar Therapeutics stock - MSN
Larimar Therapeutics (NASDAQ:LRMR) Earns “Buy” Rating from HC Wainwright - Defense World
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia - MSN
Larimar Therapeutics' SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Sells 6,488 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics’ SWOT analysis: stock potential hinges on FA treatment By Investing.com - Investing.com Nigeria
Larimar Therapeutics' (LRMR) Buy Rating Reiterated at HC Wainwright - MarketBeat
Larimar Therapeutics, Inc. Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Marketscreener.com
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia - Business Upturn
Larimar Therapeutics Begins Pediatric Dosing of Nomlabofusp for Friedreich's Ataxia Treatment - StockTitan
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress - MSN
Barclays PLC Buys 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Brokerages Set Larimar Therapeutics, Inc. (NASDAQ:LRMR) PT at $20.43 - MarketBeat
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock - Yahoo Finance
Geode Capital Management LLC Decreases Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Geode Capital Management LLC Has $5.90 Million Stock Holdings in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - MarketBeat
Barclays PLC Acquires 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better (NASDAQ:LRMR) - Seeking Alpha
Jane Street Group LLC Acquires 50,622 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Franklin Resources Inc. Acquires 3,549 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Why Is Larimar Therapeutics Stock Trading Lower On Monday? - AOL
XTX Topco Ltd Buys New Shares in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
What is HC Wainwright’s Forecast for LRMR FY2025 Earnings? - Defense World
William Blair Has Negative Estimate for LRMR Q1 Earnings - Defense World
FY2025 Earnings Estimate for LRMR Issued By HC Wainwright - MarketBeat
William Blair Has Pessimistic Outlook of LRMR Q1 Earnings - MarketBeat
Charles Schwab Investment Management Inc. Lowers Stake in Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
0.82%
0.53%
자본화:
|
볼륨(24시간):